Rockwell Medical, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Mark Strobeck
- Full Time Employees
- 157
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 30142 South Wixom road Wixom MI United States of America 48393
- IPO Date
- Jan 27, 1998
- CIK
- 0001041024
- Website
- rockwellmed.com
- Similar Companies
- Business
- Rockwell Medical, Inc. (Nasdaq: RMTI) develops, manufactures, commercializes and distributes hemodialysis concentrates and specialty pharmaceutical products for dialysis providers serving patients with end-stage renal disease worldwide. The company offers a broad portfolio of hemodialysis solutions, including liquid and dry acid concentrates such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate and RenalPure acid concentrate; bicarbonate concentrates such as RenalPure bicarbonate concentrate, Sterilyte bicarbonate concentrate; hemodialysis concentrates including Centrisol and Renasol; the DAMX dry acid concentrate mixer and DAMX45 system; iron therapy products such as Triferic dialysate and IV for iron replacement to maintain hemoglobin levels; calcitriol, an active vitamin D generic for treating secondary hyperparathyroidism; and ancillary products including 5% acetic acid, cleaners, citric acid descaler, water softener salt pellets and dialysis kits. Rockwell Medical operates manufacturing and distribution facilities in the United States, serving dialysis clinics domestically and through distribution partners internationally with a focus on the U.S. outpatient market and expansion into Latin America; founded in 1996 and headquartered in Wixom, Michigan. In 2025, the company signed a three-year multi-million dollar partnership agreement with Innovative Renal Care, one of the largest U.S. dialysis providers, to supply liquid and dry acid and bicarbonate concentrates along with the DAMX system for use across IRC's facilities; entered a multi-year product purchase agreement with the world's leading dialysis products provider expected to generate over $10 million in net sales; secured several new long-term product purchasing agreements with university medical centers; and projects net sales of $65 million to $70 million for the year amid strategic shifts toward higher-margin products and at-home dialysis expansion.
Company News
Rockwell Medical, Inc. (RMTI) Q2 2026 Earnings Call Transcript
Rockwell Medical (RMTI) Reports Q2 Loss, Lags Revenue Estimates
Rockwell Medical Announces Second Quarter 2026 Results
Rockwell Medical Announces Second Quarter 2026 Results
Rockwell Medical (RMTI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Rockwell Medical Advances Quality and Regulatory Leadership
Rockwell Medical Regains Compliance with Nasdaq Listing Requirements
Rockwell Medical to Release Second Quarter 2026 Results on Thursday, August 13, 2026
Rockwell Medical Announces 1-for-10 Reverse Stock Split
Rockwell Medical Renews Product Purchase Agreement with aQua Dialysis
Rockwell Medical Signs New 3-Year Product Purchase Agreement with Heritage Dialysis
Rockwell Medical Signs New 3-Year Product Purchase Agreement with Heritage Dialysis
Rockwell Medical, Inc. (RMTI) Q1 2026 Earnings Call Transcript
Rockwell Medical (RMTI) Reports Q1 Loss, Misses Revenue Estimates
Rockwell Medical Announces First Quarter 2026 Results and Additional 2026 Guidance with Focus on Profitability
Rockwell Medical to Release First Quarter 2026 Results on Thursday, May 7, 2026
Should Value Investors Buy Rockwell Medical (RMTI) Stock?
Fast-paced Momentum Stock Rockwell Medical (RMTI) Is Still Trading at a Bargain
Rockwell Medical, Inc. (RMTI) Q4 2025 Earnings Call Transcript
Rockwell Medical (RMTI) Reports Q4 Loss, Misses Revenue Estimates